Another Phase II randomized controlled trial evaluated the combination of oral HDAC inhibitor Entinostat (10 mg once weekly, administered in two divided doses) with Erlotinib (150 mg daily) in 132 patients with advanced NSCLC who had failed chemotherapy. The gene discussed is HDAC9; the disease is non-small cell lung carcinoma.